The effect of schedule, protein binding and growth factors on the activity of suramin
- 17 July 1992
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 51 (6) , 921-926
- https://doi.org/10.1002/ijc.2910510615
Abstract
Suramin has been shown to have antiproliferative activity, either by blocking the binding of growth factors to their receptors or by inhibiting critical cellular enzymes. In 6 different cell lines from 5 tumour types (MCF‐7, MCF‐7/ADRR, PC3, HT‐29, UM‐SCC‐IIB and SW‐1573/1R500), we studied the effect of scheduling of suramin, of FCS and of human serum albumin (HSA), of epidermal growth factor (EGF) and of the addition of growth factors in serum‐free medium on the activity of suramin. The concentration of suramin which gave 50% growth inhibition (IC50) varied from 45 μM in SW‐I573/IR500 to 153 μM in PC3 cells grown in medium supplemented with 5% FCS, after 6 days of continuous exposure. Exposure for more than 4 days did not enhance the sensitivity to suramin, except in PC3. At exposure to suramin for 1 day followed by 5 days recovery, high IC50 values (>0.5 mM) were observed in MCF‐7 cells. In medium with 1% and 0.5% FCS these values were 3 to 8 and 14 to 26 times lower respectively. Addition of HSA increased the IC50 in PC3 and MCF‐7 cells. Suramin binding to protein was dependent on the concentration of protein and of suramin. Excess of EGF in medium with different FCS concentrations did not change the IC50 values of suramin in PC3 and MCF‐7 cells. Addition of EGF, fibroblast growth factor or platelet‐derived growth factor in PC3 cells cultured in serum‐free medium did not increase the IC50 values. Suramin was active against these 6 cell lines at clinically achievable concentrations. This activity varied depending on the cell line, exposure time and suramin concentration. The most significant factor interfering with sensitivity to suramin was the amount of protein present in the culture medium.Keywords
This publication has 17 references indexed in Scilit:
- Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testingEuropean Journal of Cancer and Clinical Oncology, 1991
- Suramin Blockade of Insulinlike Growth Factor I-Stimulated Proliferation of Human Osteosarcoma CellsJNCI Journal of the National Cancer Institute, 1990
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990
- Antiproliferative effects of suramin on androgen responsive tumour cellsEuropean Journal of Cancer and Clinical Oncology, 1990
- Suramin, an anti‐cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2AFEBS Letters, 1989
- Influence of pH on the binding of suramin to human serum albuminBiochemical Pharmacology, 1989
- Rapid high-performance liquid chromatographic Determination of suramin in plasma of patients With acquired immune deficiency syndrome (AIDS) or AIDS-related complex (ARC)Journal of Pharmaceutical and Biomedical Analysis, 1989
- EFFECTS OF SURAMIN ON HTLV-III/LAV INFECTION PRESENTING AS KAPOSI'S SARCOMA OR AIDS-RELATED COMPLEX: CLINICAL PHARMACOLOGY AND SUPPRESSION OF VIRUS REPLICATION IN VIVOThe Lancet, 1985
- Suramin Protection of T Cells in Vitro Against Infectivity and Cytopathic Effect of HTLV-IIIScience, 1984
- Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor virusesCancer Letters, 1979